Whitehawk Therapeutics Advances ADC Pipeline with Phase 1 Trials, Cash Runway to 2028
Event summary
- Phase 1 trials for HWK-007 and HWK-016 ongoing, with IND submission for HWK-206 planned for mid-2026.
- Cash position of $123.0 million as of March 31, 2026, expected to fund operations into 2028.
- Presented preclinical data at AACR 2026 showing potent tumor regressions and favorable tolerability for HWK-007, HWK-016, and HWK-206.
- Reported net loss of $22.2 million for Q1 2026, compared to net income of $73.0 million in Q1 2025 (which included a $87.4 million gain from the sale of Aadi Subsidiary).
- Initial Phase 1 data for HWK-007 and HWK-016 expected in 1H 2027.
The big picture
Whitehawk Therapeutics is advancing its next-generation ADC portfolio, leveraging its proprietary CBCR platform to target difficult-to-treat cancers. The company's strategic focus on high-quality execution and preclinical proof-of-concept data positions it within the competitive oncology therapeutics landscape. With a cash runway extending into 2028, Whitehawk aims to deliver meaningful benefits for patients while navigating the challenges of clinical development and regulatory approvals.
What we're watching
- Clinical Progress
- How the pace of Phase 1 trial enrollment and data readouts for HWK-007 and HWK-016 will impact Whitehawk's valuation and strategic positioning.
- Regulatory Milestones
- Whether the mid-2026 IND submission for HWK-206 will proceed as planned and the potential implications for its development timeline.
- Financial Sustainability
- The extent to which Whitehawk's current cash position will support its operations into 2028 and whether additional funding will be required.
Related topics